Summary
This chapter outlines the generation and application of human papillomavirus type 33 (HPV 33) pseudovirions. These pseudovirions are structurally indistinguishable from native virions and are therefore valuable tools for the study of papillomavirus/cell interactions. The method describes (1) the construction of vaccinia viruses recombinant for the major and minor HPV capsid proteins, L1 and L2, respectively, (2) the transfection of Cos7 cells with a marker plasmid replicating to high copy numbers, (3) the expression of L1 and L2 using the vaccinia virus expression system, (4) the extraction, purification, and analysis of HPV-33 pseudovirions, (5) pseudoinfection assays, (6) pre- and post-attachment neutralization of pseudovirions, and (7) the use of inhibitors for study of binding and uptake of pseudovirions. The methods described have been successfully adopted for HPV 16 and 18 and may thus be applied for other HPV types, too.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Unckell, F., Streeck, R. E., and Sapp, M. (1997) Generation and neutralization of pseudovirions of human papillomavirus type 33. J. Virol. 71, 2934–2939.
Stauffer, Y., Raj, K., Masternak, K., and Beard, P. (1998) Infectious human papillomavirus type 18 pseudovirions. J. Mol. Biol. 283, 529–536.
Krauzewicz, N., Stokrova, J., Jenkins, C., Elliott, M., Higgins, C. F., and Griffin, B. E. (2000) Virus-like gene transfer into cells mediated by polyoma virus pseudocapsids. Gene Ther. 7, 2122–2131.
McMurray, H. R., Nguyen, D., Westbrook, T. F., and McAnce, D. J. (2001) Biology of human papillomaviruses. Int. J. Exp. Pathol. 82, 15–33.
Howley, P. M. (1996) In Fields Virology Vol. 2, (Fields, B. N., Knipe, D. M., Howley P. M., et al., eds.), Lippincott-Raven Publishers, Philadelphia, pp. 2045–2076.
Touze, A. and Coursaget, P. (1998) In vitro gene transfer using human papillomavirus-like particles. Nucl. Acids Res. 26, 1317–1323.
Kawana, K., Yoshikawa, H., Taketani, Y., Yoshiike, K., and Kanda, T. (1998) In vitro construction of pseudovirions of human papillomavirus type 16: incorporation of plasmid DNA into reassembled L1/L2 capsids. J. Virol. 72, 10,298–10,300.
Müller, M., Gissmann, L., Cristiano, R. J., et al. (1995) Papillomavirus capsid binding and uptake by cells from different tissues and species. J. Virol. 69, 948–954.
Yeager, M. D., Aste-Amezaga, M., Brown, D. R., et al. (2000) Neutralization of human papillomavirus (HPV) pseudovirions: a novel and efficient approach to detect and characterize HPV neutralizing antibodies. Virology 278, 570–577.
Fligge, C., Schäfer, F., Selinka, H. C., Sapp, C., and Sapp, M. (2001) DNA-induced structural changes in the papillomavirus capsid. J. Virol. 75, 7727–7731.
Schäfer, F., Florin, L., and Sapp, M. (2002) DNA binding of L1 is required for human papillomavirus morphogenesis in vivo. Virology 295, 172–181.
Moss, B., Elroy-Stein, O., Mizukami, T., Alexander, W. A., and Fuerst, T. R. (1990) New mammalian expression vectors. Nature 348, 91–92.
Beaudenon, S., Kremsdorf, D., Croissant, O., Jablonska, S., Wain-Hobson, S., and Orth, G. (1986) A novel type of human papillomavirus associated with genital neoplasias. Nature 321, 246–249.
Giroglou, T., Sapp, M., Lane, C., et al. (2001) Immunological analyses of human papillomavirus capsids. Vaccine 19, 1783–1793.
Sapp, M., Kraus, U., Volpers, C., Snijders, P. J., Walboomers, J. M., and Streeck, R. E. (1994) Analysis of type-restricted and cross-reactive epitopes on virus-like particles of human papillomavirus type 33 and in infected tissues using monoclonal antibodies to the major capsid protein. J. Gen. Virol. 75, 3375–3383.
Volpers, C., Sapp, M., Snijders, P. J., Walboomers, J. M., and Streeck, R. E. (1995) Conformational and linear epitopes on virus-like particles of human papillomavirus type 33 identified by monoclonal antibodies to the minor capsid protein L2. J. Gen. Virol. 76, 2661–2667.
Fuerst, T. R., Niles, E. G., Studier, F. W., and Moss, B. (1986) Eukaryotic transient-expression system based on recombinant vaccinia virus that synthesizes bacteriophage T7 RNA polymerase. Proc. Natl. Acad. Sci. USA 83, 8122–8126.
Zhao, K. N., Sun, X. Y., Frazer, I. H., and Zhou, J. (1998) DNA packaging by L1 and L2 capsid proteins of bovine papillomavirus type 1. Virology 243, 482–491.
Buck, C. B., Pastrana, D. V., Lowy, D. R., and Schiller, J. T. (2004) Efficient intracellular assembl of papillomaviral vectors. J. Virol. 78, 751–757.
20. Selinka, H. C., Giroglou, T., Nowak, T., Christensen, N. D., and Sapp, M. (2003) Further evidence that papillomavirus particles exist in two distinct conformations. J. Virol. 77, 12,961–12,967.
Giroglou, T., Florin, L., Schäfer, F., Streeck, R. E., and Sapp, M. (2001) Human papillomavirus infection requires cell surface heparan sulfate. J. Virol. 75, 1565–1570.
Shafti-Keramat, S., Handisurya, A., Kriehuber, E., Meneguzzi, G., Slupetzky, K., and Kirnbauer, R. (2003) Different heparan sulfate proteoglycans serve as cellular receptors for human papillomaviruses. J. Virol. 77, 13,125–13,135.
Combita, A. L., Touze, A., Bousarghin, L., Sizaret, P. Y., Munoz, N., and Coursaget, P. (2001) Gene transfer using human papillomavirus pseudovirions varies according to virus genotype and requires cell surface heparan sulfate. FEMS Microbiol. Lett. 204, 183–188.
Selinka, H. C., Giroglou, T., and Sapp, M. (2002) Analysis of the infectious entry pathway of human papillomavirus type 33 pseudovirions. Virology 299, 279–287.
Wiklund, L., Sokolowski, M., Carlsson, A., Rush, M., and Schwartz, S. (2002) Inhibition of translation by UAUUUAU and UAUUUUUAU motifs of the AU-rich RNA instability element in the HPV-1 late 3′ untranslated region. J. Biol. Chem. 277, 40,462–40,471.
Oberg, D., Collier, B., Zhao, X., and Schwartz, S. (2003) Mutational inactivation of two distinct negative RNA elements in the human papillomavirus type 16 L2 coding region induces production of high levels of L2 in human cells. J. Virol. 77, 11,674–11,684.
Zhou, J., Liu, W. J., Peng, S. W., Sun, X. Y., and Frazer, I. (1999) Papillomavirus capsid protein expression level depends on the match between codon usage and tRNA availability. J. Virol. 73, 4972–4982.
Leder, C., Kleinschmidt, J. A., Wiethe, C., and Müller, M. (2001) Enhancement of capsid gene expression: preparing the human papillomavirus type 16 major structural gene L1 for DNA vaccination purposes. J. Virol. 75, 9201–9209.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2005 Humana Press Inc.
About this protocol
Cite this protocol
Sapp, M., Selinka, HC. (2005). Generation and Applications of HPV Pseudovirions Using Vaccinia Virus. In: Davy, C., Doorbar, J. (eds) Human Papillomaviruses. Methods in Molecular Medicine, vol 119. Humana Press. https://doi.org/10.1385/1-59259-982-6:463
Download citation
DOI: https://doi.org/10.1385/1-59259-982-6:463
Publisher Name: Humana Press
Print ISBN: 978-1-58829-373-2
Online ISBN: 978-1-59259-982-0
eBook Packages: Springer Protocols